ライフサイエンスコーパス: United States Food and Drug Administration

1 for an investigational clinical trial by the United States Food and Drug Administration.

2 for other food commodities regulated by the United States Food and Drug Administration.

3 s a leading cause for drug withdrawal by the United States Food and Drug Administration.

4 which might accelerate drug approval by the United States Food and Drug Administration.

5 The United States Food and Drug Administration and its inter

6 at the drug under study was efficacious, the United States Food and Drug Administration and others ha

7 clinical trials, and have already led to the United States Food and Drug Administration approval of t

8 dications other than those referenced in the United States Food and Drug Administration approved labe

9 In April 2000, the United States Food and Drug Administration approved vert

10 data pertaining to the efficacy of the three United States Food and Drug Administration-approved agen

11 matory and immunosuppressive activity, and a United States Food and Drug Administration-approved clin

12 Detailed cross-validation studies using United States Food and Drug Administration-approved drug

13 or clinical purposes, we previously screened United States Food and Drug Administration-approved drug

14 of which was preliminarily compared with the United States Food and Drug Administration-approved Herc

15 g with comparable efficacy and safety to the United States Food and Drug Administration-approved inpa

16 The two United States Food and Drug Administration-approved medi

17 ture eye mask and sodium 4-phenylbutyrate, a United States Food and Drug Administration-approved oral

18 es had received regulatory approval from the United States Food and Drug Administration between 1986

19 Early international results, as well as United States Food and Drug Administration clinical tria

20 The United States Food and Drug Administration (FDA) ensures

21 This agent received approval by the United States Food and Drug Administration (FDA) in 2004

22 ntravenous (anti-D IGIV) was licensed by the United States Food and Drug Administration (FDA) in Marc

23 s the European Medicine Agency (EMA) and the United States Food and Drug Administration (FDA) may pro

24 In 2016, the United States Food and Drug Administration (FDA) removed

25 matically since 1958, when Congress gave the United States Food and Drug Administration (FDA) the aut

26 e-related macular degeneration, there are no United States Food and Drug Administration (FDA)-approve

27 an Ohio law took effect mandating use of the United States Food and Drug Administration (FDA)-approve

28 lts were scored on a 0 to 3+ scale using the United States Food and Drug Administration (FDA)-approve

29 oped in 1974 and was approved in 1995 by the United States Food and Drug Administration for administr

30 s of S. aureus, was recently approved by the United States Food and Drug Administration for adults.

31 -A monoclonal antibody (mAb) approved by the United States Food and Drug Administration for cancer th

32 ut several have received the approval of the United States Food and Drug Administration for clinical

33 t and sibutramine, have been approved by the United States Food and Drug Administration for long-term

34 gen receptor (AR) antagonist approved by the United States Food and Drug Administration for the treat

35 d ranibizumab, are currently approved by the United States Food and Drug Administration for the treat

36 serotonin reuptake inhibitor approved by the United States Food and Drug Administration for the treat

37 e, STI571, has recently been approved by the United States Food and Drug Administration for treating

38 ed hypomethylating agent, is approved by the United States Food and Drug Administration for treatment

39 On July 1, 2014, the United States Food and Drug Administration granted 'brea

40 Recently, the United States Food and Drug Administration granted accel

41 At this time, the United States Food and Drug Administration has approved

42 tly available in the European Union, but the United States Food and Drug Administration has had conce

43 The United States Food and Drug Administration has issued a

44 role in acute myocardial infarction, and the United States Food and Drug Administration has recently

45 ide intravitreal implant was approved by the United States Food and Drug Administration in April, 200

46 The United States Food and Drug Administration is concerned

47 In accordance with the United States Food and Drug Administration, progression-

48 est for a specific biomarker-approved by the United States Food and Drug Administration-qualifying a

49 The United States Food and Drug Administration recently clea

50 pression, and the black box warning from the United States Food and Drug Administration regarding the

51 'Animal Rule', can be used which allows the United States Food and Drug Administration to consider a

52 Recently, the United States Food and Drug Administration (US FDA) appr

53 ized as safe (GRAS) excipient in 1985 by the United States Food and Drug Administration (US-FDA) for

54 To evaluate the United States Food and Drug Administration use of the bl

55 nia) and Alcon (Orlando, Florida) and on the United States Food and Drug Administration web site.

56 rt of randomized trials and submitted to the United States Food and Drug Administration were also rev